OPINION

Circulating RNA in blood plasma as diagnostic tool for clinical oncology

About authors

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

Correspondence should be addressed: Elena A. Lolomadze
Oparina, 4, Moscow, 117997; moc.liamg@4242336

About paper

Funding: the study was conducted under the state assignment АААА-А18-118053190012-9 (Development of assays for early diagnosis of breast and ovarian cancers based on the analysis of RNA circulating in the peripheral blood).

Acknowledgements: we thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine of Pirogov Russian National Medical Research University (Moscow, Russia) for their help in interpreting the data and analyzing some of the results.

Author contribution: Lolomadze EA — literature analysis and preparation of the manuscript draft; Kometova VV, Rodionov VV — editing and manuscript revision

Received: 2020-06-23 Accepted: 2020-06-26 Published online: 2020-06-30
|

One of the key challenges facing today’s oncology is the discovery of early predictors of malignant neoplasms in patients’ biological samples. Liquid biopsy is a noninvasive diagnostic technique based on the detection and isolation of tumor cells, tumor-derived nucleic acid and exosomes circulating in the blood plasma of cancer patients. There is a plethora of research studies of circulating tumor DNA in patients with MN. The active proliferation of tumor cells occurs in the backdrop of altered gene expression. The presence of tissue-specific transcripts in the circulating RNA fraction suggests that levels of circulating RNA reflect the development of the primary tumor. We think that cell-free RNA circulating in the blood plasma is a promising molecular biomarker for early cancer detection.

Keywords: oncology, circulating RNA, miRNA, circulating nucleic acids, blood plasma, circulating tumor cells, biomarkers

КОММЕНТАРИИ (0)